查看购物车
  • Traditional Chinese
  • English
  • Japanese
  • Korean
医生调查：医生支持使用真实世界证据（RWE）指导治疗
市场调查报告书
商品编码
1764332

医生调查：医生支持使用真实世界证据（RWE）指导治疗

Physician Poll: Doctors Back Real-World Evidence to Guide Care
出版日期: | 出版商: FirstWord Group | 英文 | 商品交期: 最快1-2个工作天内

价格
简介目录

医生似乎普遍认可真实世界证据（RWE）在临床指南和治疗计划中的价值。

监管机构、定价和偿付机构以及製定临床指南的组织可以使用 RWE（随机对照试验之外获得的证据），但它如何影响执业医生？

本调查询问了法国、德国、义大利、西班牙、英国和美国的444位心臟科医生、内分泌学家、神经学家、肿瘤学家和风湿病学家，询问他们对 RWE 的了解和使用情况。

关键问题解答

  • 对 RWE 的了解程度如何？
  • RWE 应用于指导临床指引。
  • RWE 应用于临床决策支援工具。
  • RWE 在规划病患治疗方案方面有多大帮助？
  • 五年后，RWE 在规划患者治疗方案时将变得越来越重要。

方法论

檔案报告是基于自身的产业研究以及对产业意见领袖的深入访谈，并基于独立、简洁的分析而编写。报告对製药公司高管需要了解的关键发展和市场趋势进行了详细分析，以应对未来的机会和挑战。每份报告的重点都基于对二手文献的回顾和已发现的知识差距。基于这些初步研究，制定了基于证据、由专家指导的讨论指南，以确保研究能够解答最重要的问题。此外，采用严格的筛选标准，以确保受访者拥有足够的经验、知识和地位来就此主题发表演讲。

报告有何独特之处？

FirstWordReports 是值得信赖的行业领导者，致力于製药行业，为生物製药专业人士和决策者提供深入、可操作的洞察。深厚的行业知识使能够提供相关且有价值的洞察，帮助掌握新兴趋势，有效应对复杂挑战。凭藉广泛的研究以及来自领先专家和关键意见领袖（KOL）的独立、公正的见解，报告能够提供所需的准确性和可靠性。独家访谈和资料，以及持续的市场监测，让全面了解市场动态。报告涵盖 40 多个活跃的疾病领域，包括 KOL 洞察和定量医生调查在内的医生情报，以及行业专家对医疗事务、数位健康、销售与行销、市场准入和其他领域问题的看法，有助于做出更明智的资料驱动决策，并在快速变化的行业中保持竞争力。

简介目录

Doctors seem to widely recognise the value of real-world evidence (RWE) in clinical guidelines and treatment planning.

Regulators, pricing and reimbursement agencies, and organisations that produce clinical guidelines can draw on RWE - evidence generated outside of randomised controlled trials - but what impact is it having on practising physicians?

The poll asked 444 physicians from France, Germany, Italy, Spain, the UK and US who practise in cardiology, endocrinology, neurology, oncology and rheumatology about their knowledge and use of RWE.

Key Questions Answered:

  • How would you rate your knowledge of RWE?
  • How much do you agree or disagree with the following statement? ~RWE should be used to inform clinical guidelines.
  • How much do you agree or disagree with the following statement? ~RWE should be used to inform clinical decision-support tools.
  • How much value does RWE have for helping you to plan treatment programmes for your patients?
  • How much do you agree or disagree with the following statement? ~RWE will become increasingly important when planning treatment programmes for your patients in five years' time.

Methodology:

Dossier reports are developed from independent and concise analysis derived from original industry surveys and in-depth interviews with industry thought leaders. Reports analyse in detail significant developments and market trends that pharma executives need to understand if they are to manage the opportunities and challenges that lie ahead. The focus of each report is defined by a review of the secondary literature and any knowledge gaps identified. Based on this initial research, an evidence-based and expert-informed discussion guide is developed to ensure the research answers the most critical questions. Additionally, robust screening criteria are established to ensure that those interviewed are qualified in terms of their experience, knowledge and stature to speak on the topic.

What makes our reports different?:

FirstWord Reports, a trusted industry leader with an exclusive focus on the pharmaceutical sector, delivers in-depth, actionable insights for biopharma professionals and decision-makers. Our deep industry knowledge enables us to provide relevant and valuable insights that help you identify emerging trends and navigate complex challenges effectively. Backed by extensive research and independent, impartial insights from leading experts and KOLs, our reports deliver the accuracy and reliability you need. With exclusive access to interviews and data unavailable elsewhere, along with ongoing market monitoring, we give you a comprehensive view of market dynamics. Covering over 40 dynamic disease areas and providing physician intelligence, including KOL insights and quantitative physician surveys, as well as industry expert views on issues in medical affairs, digital health, sales & marketing, market access, and other areas, our reports empower you to make smarter, data-driven decisions and maintain a competitive edge in a fast-moving industry.